Mikio Mikami
Overview
Explore the profile of Mikio Mikami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
193
Citations
1774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimizu K, Sakamoto T, Ohashi T, Tanabe K, Hayashi I, Ikeda M, et al.
Clin Chim Acta
. 2025 Mar;
571:120219.
PMID: 40024277
Background And Aims: We identified a fully sialylated glycopeptide of the α-chain of Complement 4 binding protein (C4BP) in blood using Liquid chromatography/Mass spectrometry, which helps differentiate ovarian clear cell...
2.
Mikami M, Tanabe K, Imanishi T, Ikeda M, Hirasawa T, Yasaka M, et al.
Sci Rep
. 2024 Aug;
14(1):20000.
PMID: 39198565
Epithelial ovarian cancer (EOC) is widely recognized as the most lethal gynecological malignancy; however, its early-stage detection remains a considerable clinical challenge. To address this, we have introduced a new...
3.
Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer
Matsuo K, Shimada M, Matsuzaki S, Machida H, Shigeta S, Yoshida H, et al.
Int J Gynecol Cancer
. 2024 Aug;
34(9):1349-1358.
PMID: 39107048
Objective: The objective of this study was to assess the oncologic outcome of surgically-treated patients with early-stage, intermediate-risk cervical cancer according to postoperative therapy modality. Methods: This retrospective cohort study...
4.
Matsuo K, Chen L, Klar M, Lee M, Machida H, Mikami M, et al.
Gynecol Oncol
. 2024 May;
187:37-45.
PMID: 38713997
Objective: To assess the prognostic performance of the 2023 International Federation of Gynecology and Obstetrics (FIGO) endometrial cancer staging schema. Methods: This retrospective cohort study queried the Commission-on-Cancer's National Cancer...
5.
Kakuwa T, Watanabe T, Niino M, Kawata A, Satoh T, Matsumura N, et al.
J Obstet Gynaecol Res
. 2024 May;
50(7):1182-1191.
PMID: 38697202
Aim: Quality of care is important to reduce disease progression, and improve both survival and quality of life. The Japan Society of Gynecologic Oncology has published treatment guidelines to promote...
6.
Machida H, Matsuo K, Higashi T, Aoki D, Enomoto T, Okamoto A, et al.
J Gynecol Oncol
. 2024 Mar;
35(5):e61.
PMID: 38456587
Objective: Hospital treatment volume affects survival in patients with endometrial cancer; notably, initial treatment at high-volume centers improves survival outcomes. Our study assessed the effect of hospital treatment volume on...
7.
Yoshida H, Matsuo K, Machida H, Matsuzaki S, Maeda M, Terai Y, et al.
Int J Gynecol Cancer
. 2024 Feb;
34(4):510-518.
PMID: 38316444
Objective: To examine the association between intrauterine manipulator use and pathological factors and oncologic outcomes in patients with endometrial cancer who had laparoscopic hysterectomy in Japan. Methods: This was a...
8.
Seino M, Nagase S, Tokunaga H, Yamagami W, Kobayashi Y, Tabata T, et al.
J Gynecol Oncol
. 2023 Dec;
35(1):e15.
PMID: 38037547
The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for...
9.
Yamazaki A, Kuroda T, Kawasaki N, Kato K, Shimojima Yamamoto K, Iwasa T, et al.
J Hum Genet
. 2023 Oct;
69(1):41-45.
PMID: 37872345
Balanced chromosomal translocation is one of chromosomal variations. Carriers of balanced chromosomal translocations have an increased risk of spontaneous miscarriage. To avoid the risk, preimplantation genetic testing (PGT) using comprehensive...
10.
Kametani Y, Ito R, Ohshima S, Manabe Y, Ohno Y, Shimizu T, et al.
Front Immunol
. 2023 Jul;
14:1173728.
PMID: 37492571
Immune checkpoint inhibitors highlight the importance of anticancer immunity. However, their clinical utility and safety are limited by the low response rates and adverse effects. We focused on progesterone (P4),...